Bora Pharmaceuticals Co., Ltd. has completed the acquisition of Upsher-Smith Laboratories, LLC., a generics manufacturer and marketer based in Minnesota, from its sellers, Sawai Group Holdings and Sumitomo Corp. of Americas. 
 
Upsher-Smith becomes a wholly-owned subsidiary of Bora Group. Bobby Sheng, Chairman and CEO of Bora Group, will assume the role of Chairman for Upsher-Smith, and Rich Fisher, COO &  President of Upsher-Smith, will continue to lead operations for the business, reporting to Mr.  Sheng. 
 
Mr. Sheng said, “The acquisition of Upsher-Smith marks a significant milestone in Bora’s growth strategy as we forge ahead with our expansion plans in the U.S. market. The  acquisition also supports our CDMO strategy to grow our footprint in the U.S. and will help us meet  increased demand for our services from customers looking to partner with a trusted CDMO.”
 
Upsher-Smith’s Rich Fisher said, “Upsher-Smith’s level of expertise in the U.S. generics market, combined with Bora’s global network, will allow us to manufacture life-saving drugs for patients across the world. The closing of the acquisition is the start of a new chapter for Upsher-Smith and we  look forward to what the future holds.”  
 
Upsher-Smith, founded in 1919, provides manufacturing capabilities with a robust distribution network, and has established commercial relationships. It has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth and Maple Grove, Minnesota. The two facilities can commercialize and produce a range of dosage forms including oral solids, powders (oral and topical), and liquids.
 
Through this acquisition, Bora gains additional capacity to support its CDMO business and adds to its capability to serve customers throughout the pharmaceutical value chain, covering the entire U.S. market. 

Further reading: Bora Pharmaceuticals to Acquire Upsher-Smith for $210M